about
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaOncogenically active MYD88 mutations in human lymphomaIdentification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines.Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.Radiation therapy in the treatment of minor salivary gland tumors.Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapyDefinitive chemoradiation for primary oral cavity carcinoma: A single institution experience.Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation.The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positThe natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.The influence of limited English proficiency on outcome in patients treated with radiotherapy for head and neck cancer.Radiation dose to the brachial plexus in head-and-neck intensity-modulated radiation therapy and its relationship to tumor and nodal stage.A prognostic volumetric threshold of gross tumor volume in head and neck cancer patients treated with radiotherapyCorrelating computed tomography perfusion changes in the pharyngeal constrictor muscles during head-and-neck radiotherapy to dysphagia outcome.Race disparities attributed to volumetric tumor burden in patients with head and neck cancer treated with radiotherapy.Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.IRF4: Immunity. Malignancy! Therapy?External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer.Volumetric tumor burden and its effect on brachial plexus dosimetry in head and neck intensity-modulated radiotherapy.NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
P50
Q24613755-BC2FAF34-6B60-413A-B1E5-8E194239B2F6Q28301648-260F4F68-9701-4446-9C06-9D10F76E6DAAQ33659363-4A9F4171-7A7B-4262-804F-86646C736B29Q33924077-BC0789DF-7B07-4ACE-B2A3-E58D4EC4F33CQ35841958-50AF2332-D18A-48E1-BC3D-0EE7955C602EQ37143286-53D46F1A-EB86-4C99-B7BA-7124B19CAA40Q37156582-484A0C56-8333-439A-B7BD-AA4106BEBE3FQ37165669-ED92E8EC-E9C2-4F4B-87DF-334A5BF39A4AQ37192658-BF7B716F-1BBE-40D4-AF10-55C6291BB66FQ37213044-A4EDECF9-5BD4-4A5D-A46F-EAAFC40258A8Q37214143-2524FA62-584F-4434-86F0-758016890F4BQ37238549-4F1DA9F8-01C5-4F85-90A2-2B00DCE0468FQ37238553-AA7AA902-24E7-4C9F-B4A6-ECCC491743DFQ37238564-EA5A8622-36C6-42FE-AA77-E031E9658805Q37238573-D63C1661-A345-4C1E-A763-D7FB214BE70BQ37245950-A5D04834-B42F-48CD-8E88-B40E9AE0022BQ37257101-CC4B80C3-197A-4044-873B-747AC5B84C05Q37454043-8D86B388-6274-4FFA-8863-96F954AAB16BQ38222938-D90DE063-B00A-468C-AFC8-5788B7C8FA70Q41058917-AFAC40A6-DFF2-4C7C-8015-4A42321FA2E4Q90680882-ED4D63D5-B25E-4666-B914-5D9EF62CAB2B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul B. Romesser
@ast
Paul B. Romesser
@en
Paul B. Romesser
@es
Paul B. Romesser
@nl
Paul B. Romesser
@sl
type
label
Paul B. Romesser
@ast
Paul B. Romesser
@en
Paul B. Romesser
@es
Paul B. Romesser
@nl
Paul B. Romesser
@sl
prefLabel
Paul B. Romesser
@ast
Paul B. Romesser
@en
Paul B. Romesser
@es
Paul B. Romesser
@nl
Paul B. Romesser
@sl
P106
P1153
12772670500
P21
P31
P496
0000-0001-8268-2903